Sign In
Buy GALT
$2.97
-0.260 (-8.05%)
At Close: Jul 31, 2026
Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?
10:29am, Friday, 20'th Dec 2024
On Friday, Galectin Therapeutics, Inc. GALT released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cir
NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its globa
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks
10:35am, Monday, 09'th Dec 2024
The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of th
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
08:00am, Thursday, 14'th Nov 2024
NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts f
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08:30am, Tuesday, 03'rd Sep 2024
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chie
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
08:00am, Tuesday, 13'th Aug 2024
NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
08:00am, Thursday, 01'st Aug 2024
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khu
Meet the 10 biggest megadonors in the 2024 election cycle so far
01:47pm, Tuesday, 18'th Jun 2024
Following record-breaking fundraising by candidates in the 2022 midterms, this year's election cycle is shaping up to be another big one for megadonors.
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
08:00am, Tuesday, 04'th Jun 2024
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
08:00am, Wednesday, 15'th May 2024
NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and pr
GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023
08:52am, Friday, 05'th Apr 2024
Galectin Therapeutics (NASDAQ: GALT ) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents.
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
08:00am, Friday, 29'th Mar 2024
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and
Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point
08:11pm, Wednesday, 20'th Mar 2024
Interim results from the phase 2b/3 NAVIGATE study, using Belapectin for the prevention of esophageal varices in NASH Cirrhosis patients, expected Q4 of 2024. In a prior phase 2 study, it was shown th
